biota will enjoy all the spoils-the australian, page-17

I still say 75% is way too low for trials that have already been done, and just need replicating in another market.

What do you base that assertion on? Can you clarify what "way too low" means.

I assert that the trials will not be a replication, but an entirely new set of trials designed for a different regulator and population.

I assert that DS is a major pharma with vast experience, expertise and resources, who were dealing with a regulator in their home market. None of which applies to Biota.

I assert that if this was such a slam dunk then why oh why did Biota not progress LANI prior to now.